SLAMF7

DUBLIN, March 1, 2024 /PRNewswire/ -- The "In Vitro Diagnostic (IVD) Reagents Market by Type (Antibodies, Proteins, Oligonucleotides, Nucleic Acid Probes) Technology (Immunoassay, Biochemistry, Molecular Diagnostic, Microbiology, Hematology) Use (Clinical, RUO) End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering. The global in-vitro diagnostics reagents market is projected to reach $75.67 billion by 2030, at a CAGR of 5.4% from 2023 to 2030. The growth of this market is driven by the increasing prevalence of infectious diseases, increasing funding for research activities, the rising adoption of advanced diagnostic technologies, the growth in proteomics and genomics research studies, and the growing number of clinical laboratories offering advanced diagnostic testing menus. Additionally, emerging economies and the growing demand for protein therapeutics and personalized medicines are expected to offer significant market growth opportunities. However, the stringent regulations for antigen-specific reagents restrain the growth of this market. Additionally, the high costs of reagents and the unfavorable reimbursement scenario pose a significant challenge to the market's growth. Based on type, the IVD reagents market is segmented into antibodies, purified proteins and peptides, oligonucleotides, nucleic acid probes, and other reagents. In 2023, the antibodies segment is expected to account for the largest share of the IVD reagents market. The large share of this segment is mainly attributed to the increasing R&D funding. For instance, According to Research America, investments in medical and health R&D by the U.S. has increased by 7.0% between 2019 and 2020. In 2020, the total medical and health R&D expenditure was USD 245.1 billion. Furthermore, the huge demand for antibodies in various biomedical & basic research are the factors contributing to the largest share of this segment. Based on technology, the IVD reagents market is segmented into immunoassay/immunochemistry, biochemistry/clinical chemistry, molecular diagnostics, microbiology, hematology, coagulation/hemostasis, urinalysis, and other IVD technologies. In 2023, the immunoassay/immunochemistry segment is expected to account for the largest share of the IVD reagents market. The large share of this segment is mainly attributed to the increasing use of immunoassays in infectious disease testing, the development of novel tests, and the rising demand for immunoassay-based tests. Further, the coronavirus (COVID-19) outbreak since December 2019 is expected to accelerate the growth of this segment owing to the national emergency declared and the requirement of various reagents for the kits and assay preparation. Based on the use, the IVD reagents market is segmented into clinical use, research use only (RUO), and analyte-specific reagents (ASR). In 2023, the clinical use segment is expected to account for the largest share of the IVD reagents market. The large share of this segment is mainly attributed to the growing need for the early detection of various epidemic and pandemic infections, the large volume of test samples diagnosed for clinical purposes, and initiatives undertaken by manufacturers to develop advanced IVD reagents drive the demand for IVD reagents for clinical use. Based on the end user, the IVD reagents market is segmented into IVD manufacturers, reference laboratories, academic institutes and research laboratories, and hospital laboratories. In 2023, the IVD manufacturers segment is expected to account for the largest share of the IVD reagents market. The large share of this segment is mainly attributed to the initiatives undertaken by IVD manufacturers and the increasing demand for pharmaceutical & biopharmaceutical products from emerging countries. In 2023, North America is estimated to account for the largest share of the IVD reagents market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Furthermore, in 2023, the U.S. is expected to account for the largest share of the IVD reagents market in North America. The market growth in the U.S. is attributed to the increasing prevalence of infectious diseases, growing preference for PoC testing and personalized medicine, and rising funds and investments for research reagents. Market Insights Drivers Increasing Prevalence of Infectious Diseases Increasing Funding for Research Activities Growth in Proteomics and Genomics Research Studies Growing Number of Clinical Laboratories Offering Advanced Diagnostic Testing Menus Restraints Stringent Regulations for Antigen-Specific Reagents Opportunities Growing Demand for Protein Therapeutics and Personalized Medicines Emerging Economies Challenges High Costs of Reagents and the Unfavorable Reimbursement Scenario Factor Analysis Regulatory Analysis U.S. Canada Europe China Japan India Latin America Middle East & Africa Porter's Five Forces Analysis Pricing Analysis Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments) Thermo Fisher Scientific (U.S.) Becton Dickinson and Company (U.S.) Merck KGaA (Germany) Bio-Rad Laboratories Inc. (U.S.) Agilent Technologies Inc. (U.S.) Abcam plc (U.K.) Hologic Inc. (U.S.) InBios International Inc. (U.S.) SDIX LLC (U.S.) BioTechne Corporation (U.S.) Bio-Synthesis Inc. (U.S.) RayBiotech Inc. (U.S.) Sino Biological Inc. (China) Oy Medix Biochemica Ab (Finland) QIAGEN N.V. (Netherlands) Beckman Coulter Inc. (U.S.). Competition Analysis Overview Competitive Benchmarking Competitive Dashboard Industry Leaders Market Differentiators Vanguards Emerging Companies Market Share Analysis (2022) Thermo Fisher Scientific (U.S.) Merck KGaA (Germany) Becton, Dickinson and Company (U.S.) Scope of the Report: IVD Reagents Market Size & Trend Analysis - by Type Antibodies Antibodies Market, By Type Monoclonal Antibodies Polyclonal Antibodies Antibodies Market, By Target Cluster of Differentiation (CD) T-cell Receptor (TCR) Epidermal Growth Factor Receptor (EGFR) Other Targets Purified Proteins and Peptides Oligonucleotides Nucleic Acid Probes Other Reagents Notes: 1. Other targets include Nucleic BCMA, DLL/Notch, EpCAM, HER2, PDGFR?, Claudin 18.2, SLAMF7, and DKK1. B-cell maturation antigen (BCMA). 2. Other reagents include blocking agents, detergents, surfactants, wetting agents, buffers, stabilizers, purified water, dyes, standards and controls, enzymes, cell culture reagents, and anti-coagulants. IVD Reagents Market Size & Trend Analysis - by Technology Immunoassay/Immunochemistry Enzyme-linked Immunosorbent Assays (ELISA) and Enzyme-linked Immunospot Assays (ELISpot) Lateral Flow Assays (LFA)/Rapid Tests Western Blotting (WB) Immunofluorescence (IF) Functional Assays Immunoprecipitation (IP) Other Immunoassay Technologies Biochemistry/Clinical Chemistry Molecular Diagnostics Polymerase Chain Reaction (PCR) Hybridization Isothermal Nucleic Acid Amplification Technology DNA Sequencing & Next-generation Sequencing Microarray Other Molecular Diagnostic Technologies Microbiology Hematology Coagulation/Hemostasis Urinalysis Other IVD Technologies Note: 1. Other technologies include virus neutralization tests, agar gel immunodiffusion, and radioimmunoassay. 2. Other molecular diagnostic technologies include electrophoresis, ligase chain reaction (LCR), northern blot, and southern blot. 3. Other IVD technologies include anatomical pathology, histochemistry, and whole blood glucose monitoring. IVD Reagents Market Size & Trend Analysis - by Use Clinical Use Research Use Only (RUO) Analyte-specific Reagents (ASR) IVD Reagents Market Size & Trend Analysis - by End User Reference Laboratories IVD Manufacturers Academic Institutes and Research Laboratories Hospital Laboratories IVD Reagents Market Size & Trend Analysis - by Geography North America U.S. Canada Europe Germany France Italy U.K. Spain Switzerland Netherlands Rest of Europe Asia-Pacific China Japan India South Korea Australia Singapore Rest of Asia-Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

A team of researchers has developed a nanotechnology platform that can change the way the immune system sees solid tumor cells, making them more receptive to immunotherapy. The preclinical findings suggest this adaptable immune conversion approach has the potential for broad application across many cancer types. A team of researchers at The University of Texas MD Anderson Cancer Center has developed a nanotechnology platform that can change the way the immune system sees solid tumor cells, making them more receptive to immunotherapy. The preclinical findings suggest this adaptable immune conversion approach has the potential for broad application across many cancer types. The study, published today in Nature Nanotechnology, details the use of this platform to artificially attach an activation molecule to the surface of tumor cells, triggering an immune response in both in vivo and in vitro models. Wen Jiang, M.D., Ph.D., assistant professor of Radiation Oncology, and Betty Kim, M.D., Ph.D., professor of Neurosurgery, co-led the study. "With this new platform, we now have a strategy to convert a solid tumor, at least immunologically, to resemble a hematological tumor, which often has a much higher response rate to immunotherapy treatments," Jiang said. "If we are able to translate and validate this approach in the clinic, it may enable us to get closer to the maximum level of activity from immunotherapy drugs with cancers that have not traditionally responded well." Immunotherapy has high response rates in blood cancers like leukemia and lymphoma, but success has been variable across solid tumors. Scientists have been working to further understand the mechanisms prohibiting a better response. One explanation is that varied expression of immune regulatory molecules on blood cancer versus solid tumor cells impact how they interact with immune cells. The signaling lymphocytic activation molecule family member 7 (SLAMF7) receptor is critical in activating the body's immune cells against cancer cells, acting as an "eat me" signal. However, it is found almost exclusively on the surface of blood cancer cells and not in solid tumor cells, making it an attractive target for the researchers' immune conversion approach. To promote the expression of SLAMF7 on solid tumor cells, the researchers developed their bispecific tumor-transforming nanoconjugate (BiTN) platform. These nanosystems are designed with one molecule to bind to the surface of targeted tumor cells and a second molecule to activate an immune response. In this study, the researchers used BiTN with SLAMF7 and a HER2-recognizing antibody to target HER2-positive breast cancer cells. In laboratory models, the nanoconjugate successfully attached SLAMF7 to the breast cancer cells, resulting in phagocytosis, or ingestion, by immune cells. The approach also sensitized the breast cancer cells to treatment with an anti-CD47 antibody, which blocks the "don't eat me" signal from tumor cells to further increase responses in solid tumors. According to the authors, one of the most exciting things about this platform is its broad potential applications. The approach would not be specific to one cancer type or one regulatory molecule, rather it has the potential to be a universal strategy for several different solid tumor types. As a proof of concept, the authors also developed BiTN with folate instead of the anti-HER2-antibody to target triple-negative breast cancer with similar results. "Because these are engineered constructs, this can be used as a plug-and-play approach to incorporate different tumor-targeting agents or immune molecules onto the surface of the nanoparticle," Kim said. "For patients with solid tumors that have not responded to immunotherapy, we see this as an added advantage to target the part of the tumor that didn't respond." The study was supported in part by the Susan G. Komen Foundation Career Catalyst Research Grant, the National Cancer Institute/National Institutes of Health (1K08 CA241070, P30 CA016672) and the United States Department of Defense.

AUSTIN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the third quarter of 2021. “We are focused on execution across our growing portfolio of wholly owned next-generation ETBs,” said Eric Poma, Ph.D., Molecular Templates’ Chief Executive and Scientific Officer. “Third quarter highlights included the initiation of clinical development of MT-6402 (targeting PD-L1 via dual mechanisms), the initiation of the HER2-positive breast cancer expansion cohort for MT-5111 as well as continued enrollment of patients in our MT-0169 clinical program. These programs demonstrate the depth and versatility of our ETB platform and the potential to develop innovative treatments for a broad array of solid and hematological tumors with high unmet medical need." Company Highlights and Upcoming Milestones Corporate In July 2021, MTEM dosed its first subject in a Phase 1 study of MT-6402. MT-6402 is the first of MTEM’s 3rd generation ETBs incorporating Antigen Seeding Technology to enter the clinic and represents a new approach to immuno-oncology. On August 4, 2021, MTEM assumed full rights to TAK-169, now known as MT-0169, from its former co-development partner, Takeda, including full control of MT-0169 clinical development. Enrollment in the MT-0169 Phase 1 study in relapsed/refractory multiple myeloma has resumed after the transfer of the IND to MTEM. MTEM expects to provide an update on MT-5111, MT-0169 and MT-6402 by the end of this year and expects to provide periodic updates throughout 2022. MT-0169 (CD38 ETB) On August 4, 2021, MTEM assumed full rights to MT-0169 from its former co-development partner, Takeda, including full control of MT-0169 clinical development, per the terms of the terminated collaboration agreement with Takeda. MTEM will continue conducting the ongoing Phase 1 study for MT-0169 in relapsed/refractory multiple myeloma and non-Hodgkin’s lymphoma. Patient enrollment in the 50 mcg/kg cohort is currently ongoing. MTEM continues to see pharmacodynamic activity with MT-0169. Data on the first four patients treated in the Phase 1 study evaluating MT-0169 was presented in a poster at the Society for Immunotherapy of Cancer (SITC) annual meeting on November 12. MT-6402 (PD-L1 ETB with Antigen Seeding Technology) MTEM is enrolling patients in the Phase 1 study of MT-6402 which initiated in July 2021. MT-6402 is the first of MTEM’s 3rd generation ETBs to enter the clinic. It was designed to induce potent anti-tumor effects via PD-L1 targeting through multiple mechanisms that may overcome the limitations of PD-L1 antibody therapies. The Phase 1 study is a multi-center, open-label, dose escalation and dose expansion trial in the United States. Patients with confirmed PD-L1 expressing tumors or confirmed PD-L1 expression in the tumor microenvironment are eligible for enrollment. Patient enrollment in the 16 mcg/kg cohort (the starting dose) is currently ongoing. There have been no dose limiting toxicities and no signs of capillary leak syndrome observed to date. Following determination of the maximum tolerated dose (MTD) or recommended Phase 2 dose, expansion cohorts are planned to evaluate MT-6402 as a monotherapy in tumor-specific and tumor-agnostic cohorts. MT-5111 (HER2 ETB) The Phase 1 study of MT-5111 in HER2-positive cancers is ongoing with multiple sites open for enrollment. The HER2-positive breast cancer expansion cohort initiated as of November 2021 at a dose of 10 mcg/kg (anticipated to be a therapeutic dose level). Dose escalation will continue to determine the recommended Phase 2 dose while the breast cancer expansion cohort collects efficacy and safety data. Research MTEM continues to advance its pipeline of next-generation ETBs targeting CTLA-4, TIGIT, TROP2, SLAMF-7, CD20, and CD45. A poster on ETB mediated depletion of TIGIT expressing immune cells for cancer immunotherapy was presented at the SITC annual meeting on November 13. Through 2021 and in 2022, MTEM expects to present preclinical data on ETB candidates at medical and scientific conferences. Upcoming Investor Events Stifel Healthcare Conference (November 15-17, 2021) Evercore ISI 4th Annual HealthCONx (November 30 – December 2, 2021) Financial Results The net loss attributable to common shareholders for the third quarter of 2021 was $30.4 million, or $0.54 per basic and diluted share. This compares with a net loss attributable to common shareholders of $23.2 million, or $0.47 per basic and diluted share, for the same period in 2020. Revenues for the third quarter of 2021 were $2.4 million, compared to $4.3 million for the same period in 2020. Revenues for the third quarter of 2021 were comprised of revenues from collaborative research and development agreements with Vertex and Bristol Myers Squibb. Total research and development expenses for the third quarter of 2021 were $22.9 million, compared with $19.6 million for the same period in 2020. Total general and administrative expenses for the third quarter of 2021 were $9.0 million, compared with $7.5 million for the same period in 2020. As of September 30, 2021, MTEM’s cash and investments totaled $175.4 million. MTEM’s current cash and investments are expected to fund operations into the second half of 2023. About Molecular Templates Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases. Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Molecular Templates disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act’s Safe Harbor for forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Molecular Templates may identify forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the safety or potential efficacy of Molecular Templates’ drug or biologic candidates, including the anticipated benefits of Molecular Templates’ next-generation ETBs compared to its first-generation ETBs; statements relating to the development of MT-5111, MT-0169, and MT-6402; the expected timing of submitting various IND applications and conducting studies and generating data;Molecular Templates’ receipt of future development, regulatory and sales milestones and royalty payments; the expected participation and presentation at upcoming conferences; the anticipated effects of the COVID-19 pandemic on Molecular Templates’ ongoing clinical studies, manufacturing and preclinical development; and Molecular Templates’ belief that its proprietary biologic drug platform technology, or ETBs, provides for a differentiated mechanism of action that may address some of the limitations associated with currently available cancer therapeutics. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to, the uncertainties inherent in the preclinical and clinical development process; whether Molecular Templates’ cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; Molecular Templates’ ability to timely enroll patients in its clinical trials; the ability of Molecular Templates’ to protect its intellectual property rights; risks from global pandemics including COVID-19; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading “Risk Factors” in Molecular Templates’ filings with the SEC. There can be no assurance that any of Molecular Templates’ drug or biologic candidates will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise. Contacts: Sean McLennan Interim Chief Financial Officer sean.mclennan@mtem.com 512-334-6664 Joyce Allaire LifeSci Advisors, LLC jallaire@lifesciadvisors.com Molecular Templates, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) (unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Research and development revenue, related party $ — $ 1,566 $ 13,136 $ 4,962 Research and development revenue, other 2,379 2,732 7,597 7,176 Grant revenue — — — 3,210 Total revenue 2,379 4,298 20,733 15,348 Operating expenses: Research and development 22,881 19,622 65,328 70,667 General and administrative 9,027 7,547 26,178 19,606 Total operating expenses 31,908 27,169 91,506 90,273 Loss from operations 29,529 22,871 70,773 74,925 Interest and other income, net 175 167 308 925 Interest and other expense, net (1,033 ) (521 ) (2,301 ) (1,229 ) Loss on extinguishment of debt — — — (1,237 ) Loss before provision for income taxes 30,387 23,225 72,766 76,466 Provision for income taxes — — — 5 Net loss 30,387 23,225 72,766 76,471 Net loss attributable to common shareholders $ 30,387 $ 23,225 $ 72,766 $ 76,471 Net loss per share attributable to common shareholders: Basic and diluted $ 0.54 $ 0.47 $ 1.32 $ 1.63 Weighted average number of shares used in net loss per share calculations: Basic and diluted 56,174,644 49,026,499 54,958,365 46,808,437 Molecular Templates, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) September 30, 2021(unaudited) December 31, 2020 ASSETS Current assets: Cash and cash equivalents $ 27,593 $ 25,218 Marketable securities, current 141,783 68,667 Prepaid expenses 7,623 6,080 Accounts receivable, related party — 234 Other current assets 445 1,125 Total current assets 177,444 101,324 Marketable securities, non-current 6,013 — Operating lease right-of-use assets 9,002 11,104 Property and equipment, net 20,451 22,254 Other assets 5,019 5,195 Total assets $ 217,929 $ 139,877 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 1,311 $ 2,350 Accrued liabilities 11,305 12,575 Deferred revenue, current 32,240 14,014 Deferred revenue, current, related party — 789 Other current liabilities, related party — 5,614 Other current liabilities 2,541 2,211 Total current liabilities 47,397 37,553 Deferred revenue, long-term 51,302 4,538 Deferred revenue, long-term, related party — 3,106 Long-term debt, net of current portion 35,251 14,926 Operating lease liabilities 10,284 12,213 Other liabilities, related party — 6,711 Other liabilities 1,590 1,490 Total liabilities 145,824 80,537 Commitments and contingencies (Note 10) Stockholders’ equity Preferred stock, $0.001 par value: Authorized: 2,000,000 shares at September 30, 2021 and December 31, 2020; issued and outstanding: 250 shares at September 30, 2021 and December 31, 2020 — — Common stock, $0.001 par value: Authorized: 150,000,000 shares at September 30, 2021 and December 31, 2020; issued and outstanding: 56,297,967 shares at September 30, 2021 and 49,984,333 shares at December 31, 2020 56 50 Additional paid-in capital 413,857 328,314 Accumulated other comprehensive income, (loss) (1 ) 17 Accumulated deficit (341,807 ) (269,041 ) Total stockholders’ equity 72,105 59,340 Total liabilities and stockholders’ equity $ 217,929 $ 139,877